Having shown preclinical promise, the first clinical data are now in on natural killer cells equipped with a chimeric antigen receptor targeting CD19. Albeit in a small number of patients so far, the experimental immunotherapy has elicited a high response rate with little to no toxicity.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.